SCHEMBL7066063

SCHEMBL7066063

COc1ccc2[nH]c(-c3ccccc3C=O)cc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
KDM4E B2RXH2 3/20 0.59
MAPT P10636 3/20 0.59
RAB9A P51151 3/20 0.59
NPC1 O15118 2/20 0.59
AURKA O14965 1/20 0.54
KDR P35968 1/20 0.54
ITK Q08881 2/20 0.50
CA2 P00918 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA9 Q16790 1/20 0.48
PDGFRB P09619 3/20 0.48
PDGFRA P16234 3/20 0.48
FLT3 P36888 1/20 0.48
AXL P30530 1/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7066067 0.84 KDM4E (0.57) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL7066125 0.81 AURKA (0.60) KDM4EAURKAKDRPDGFRBPDGFRA
SCHEMBL5716726 0.79 KDR (0.57) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL9469072 0.79 KDM4E (0.64) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL6118322 0.79 RAB9A (0.64) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL25175575 0.77 KDM4E (0.62) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL6303491 0.77 KDM4E (0.61) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL30064624 0.76 KDM4E (0.57) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL28545417 0.76 KDM4E (0.57) MEN1KMT2AKDM4EMAPTRAB9A
SCHEMBL7608310 0.76 KDM4E (0.39) MEN1KMT2AKDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents BAXTER ONCOLOGY GMBH 2003-08-21 US disclosed
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents BECKERS THOMAS (DE) 2002-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT MEN1 1405/4885KMT2A 554/4885KDM4E 2155/4885
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT MEN1 1405/4885KMT2A 554/4885KDM4E 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.